Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Edward Lee Carter: Every Antithrombotic Regimen Needs an Exit Strategy – Lessons from the OPTIMA-AF Trial
Edward Lee Carter/LinkedIn
Aug 2, 2026, 03:48

Edward Lee Carter: Every Antithrombotic Regimen Needs an Exit Strategy – Lessons from the OPTIMA-AF Trial

Edward Lee Carter, Clinical Pharmacist Practitioner at U.S. Department of Veterans Affairs, shared a post on LinkedIn:

“Most antithrombotic regimens have a start date.

Far fewer have a documented stop date.

That may be one of the biggest opportunities we have to improve medication safety.

The OPTIMA-AF trial asked an important question:

After PCI in patients with atrial fibrillation, how long does dual therapy really need to continue?

In a carefully selected population undergoing imaging-guided PCI, 1 month of a DOAC plus a P2Y₁₂ inhibitor, followed by DOAC alone, significantly reduced clinically relevant bleeding while meeting the study’s predefined noninferiority criterion for ischemic outcomes.

But here’s what I found even more interesting…

OPTIMA-AF isn’t simply another PCI trial.

It’s another reminder that antithrombotic stewardship doesn’t end when therapy begins.

As clinicians, we routinely ask:

  • Which anticoagulant?
  • Which P2Y₁₂ inhibitor?
  • Which dose?

Maybe we should spend just as much time asking:

  • Does every antithrombotic still have a clear indication?
  • Has the patient’s bleeding risk changed?
  • Has the ischemic benefit diminished?
  • Who owns the stop date?

The trial also deserves appropriate caution.

Its patients were predominantly those with stable coronary disease, all underwent intravascular imaging-guided PCI, and the study was conducted entirely in Japan. These results should inform practice—but they should not be interpreted as meaning every patient can safely discontinue a P2Y₁₂ inhibitor after 30 days.

Clinical judgment remains essential.

For me, the broader lesson is this:

Every additional day of combination antithrombotic therapy should be an intentional decision—not simply the default.

That may be the next frontier of antithrombotic stewardship.

  • Swipe through the carousel for a summary of the trial, its limitations, and a practical stewardship framework.

How does your institution approach planned de-escalation of antithrombotic therapy after PCI? Is the anticipated stop date documented when the patient leaves the hospital?”

Edward Lee Carter: Every Antithrombotic Regimen Needs an Exit Strategy - Lessons from the OPTIMA-AF Trial

Other posts featuring Edward Lee Carter on Hemostasis Today.

Edward Lee Carter Health Hematology Hemostasis Hemostasis News Hemostasis Today https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00665-3/abstract OPTIMA-AF trial
NewsFeed